Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Kim HR"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 37
Tytuł:
Real-world outcome of crizotinib for anaplastic lymphoma kinase-positive lung cancer: Multicenter retrospective analysis in South Korea.
Autorzy:
Jeon DS; Department of Pulmonary and Critical Care Medicine, Nowon Eulji Medical Center, University of Eulji, Seoul, South Korea.
Park CK; Department of Pulmonary and Critical Care Medicine, Chonnam National University Hwasun hospital, Chonnam National University, Jeollanam-do, Republic of Korea.
Kim SJ; Department of Internal Medicine, Postech-Catholic Biomedical Engineering Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Park CK; Department of Pulmonary and Critical Care Medicine, Catholic University of Korean Yeouido Saint Mary's Hospital, Seoul, Korea.
Chang YS; Department of Internal Medicine, Yonsei University College of Medicine, 8th Floor Annex Building, Yongdong Severance Hospital, Seoul, Republic of Korea.
Jung CY; Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
Lee SY; Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Lee SY; Division of Pulmonary and Critical Care Medicine, Kyungpook National University Chilgok Hospital, Daegu, Korea.
Ryu JS; Department of Pulmonary and Critical Care Medicine, Inha University Hospital, Incheon, Republic of Korea.
Lee JE; Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.
Lee KY; Department of Pulmonary Medicine, Konkuk University School of Medicine, Seoul, Republic of Korea.
Jang TW; Department of Internal Medicine, Kosin University Medical College, Pusan, Korea.
Jang SH; Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
Yoon SH; Department of Internal Medicine, School of Medicine, Pusan National University, Yangsan, Republic of Korea.
Lee SH; Division of Pulmonology, Institute of Chest Disease, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Choi CM; Department of Pulmonary and Critical Care Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim HR; Department of Pulmonary and Critical Care Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim YJ; Department of Pulmonary and Critical Care Medicine, Nowon Eulji Medical Center, University of Eulji, Seoul, South Korea.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Feb; Vol. 15 (6), pp. 448-457. Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Lung Neoplasms*/pathology
Carcinoma, Non-Small-Cell Lung*/pathology
Humans ; Male ; Middle Aged ; Female ; Crizotinib/therapeutic use ; Anaplastic Lymphoma Kinase/therapeutic use ; Receptor Protein-Tyrosine Kinases/therapeutic use ; Protein Kinase Inhibitors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma.
Autorzy:
Yang G; Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Kim KH; Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Lee CG; Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Hong MH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Cho Y; Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Yoon HI; Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2024 Jan; Vol. 56 (1), pp. 115-124. Date of Electronic Publication: 2023 Aug 29.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/pathology
Adenocarcinoma of Lung*/radiotherapy
Humans ; Retrospective Studies ; Progression-Free Survival ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Pre-operative clonal hematopoiesis is related to adverse outcome in lung cancer after adjuvant therapy.
Autorzy:
Yun JK; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, Republic of Korea.
Kim S; Genome Opinion Inc., Sungsu SKV1 Center, 1-721, 48, Achasan-Ro 17-Gil, Seongdong-Gu, Seoul, Republic of Korea.
An H; Genome Opinion Inc., Sungsu SKV1 Center, 1-721, 48, Achasan-Ro 17-Gil, Seongdong-Gu, Seoul, Republic of Korea.
Lee GD; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, Republic of Korea.
Kim HR; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, Republic of Korea.
Kim YH; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, Republic of Korea.
Kim DK; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, Republic of Korea.
Park SI; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, Republic of Korea.
Choi S; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, Republic of Korea. .
Koh Y; Genome Opinion Inc., Sungsu SKV1 Center, 1-721, 48, Achasan-Ro 17-Gil, Seongdong-Gu, Seoul, Republic of Korea. .; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-Ro, Jongno-Gu, Seoul, Republic of Korea. .
Pokaż więcej
Źródło:
Genome medicine [Genome Med] 2023 Dec 12; Vol. 15 (1), pp. 111. Date of Electronic Publication: 2023 Dec 12.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/genetics
Lung Neoplasms*/surgery
Carcinoma, Non-Small-Cell Lung*/therapy
Carcinoma, Non-Small-Cell Lung*/drug therapy
Humans ; Clonal Hematopoiesis ; Chemotherapy, Adjuvant/methods ; Neoplasm Staging ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.
Autorzy:
Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Sugawara S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan.
Lee JS; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul, National University Bundang Hospital, Gyeonggi-do, South Korea.
Kang JH; Department of Medical Oncology, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, South Korea.
Inui N; Department of Pulmonary Medicine, Hamamatsu University Hospital, Shizuoka, Japan.
Hida T; Department of Thoracic Oncology, Aichi Cancer Center, Aichi, Japan.
Lee KH; Department of Internal Medicine, Chungbuk National University Hospital, Chungcheongbuk-do, South Korea.
Yoshida T; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Tanaka H; Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Yang CT; Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Nishio M; Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan.
Ohe Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Tamura T; Thoracic Center, St. Luke's International Hospital, Tokyo, Japan.
Yamamoto N; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Yu CJ; Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu County, Taipei, Taiwan.
Akamatsu H; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Takahashi S; Oncology Clinical Development Planning 1, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Nakagawa K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (16), pp. 17061-17067. Date of Electronic Publication: 2023 Aug 28.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Humans ; Nivolumab/adverse effects ; Bevacizumab/adverse effects ; Paclitaxel/adverse effects ; Carboplatin/adverse effects ; Platinum ; Protein-Tyrosine Kinases ; Proto-Oncogene Proteins ; Neoplasm Recurrence, Local ; Survival Analysis ; ErbB Receptors ; Receptor Protein-Tyrosine Kinases
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma.
Autorzy:
Kim Y; Department of Pathology, Korea University College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea.
Ahn B; Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Yoon S; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Lee G; Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Kim D; Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Chun SM; Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Kim HR; Department of Thoracic and Cardiovascular Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Jang SJ; Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Hwang HS; Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Jun 22; Vol. 18 (6), pp. e0287256. Date of Electronic Publication: 2023 Jun 22 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma of Lung*/genetics
Adenocarcinoma of Lung*/surgery
Adenocarcinoma*/genetics
Adenocarcinoma*/surgery
Lung Neoplasms*/genetics
Lung Neoplasms*/surgery
Humans ; beta Catenin/genetics ; beta Catenin/metabolism ; Mutation ; ErbB Receptors/genetics ; DNA Mutational Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing.
Autorzy:
Ahn BC; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Han YJ; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Hong MH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Cho BC; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Lim SM; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2023 Apr; Vol. 55 (2), pp. 488-497. Date of Electronic Publication: 2022 Nov 09.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Antineoplastic Agents*/therapeutic use
Humans ; Female ; Middle Aged ; Male ; Retrospective Studies ; Mutation ; High-Throughput Nucleotide Sequencing
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination.
Autorzy:
Huh HD; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 Project, Yonsei University, Seoul, 03722, Republic of Korea.
Sub Y; Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Oh J; Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Kim YE; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 Project, Yonsei University, Seoul, 03722, Republic of Korea.
Lee JY; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 Project, Yonsei University, Seoul, 03722, Republic of Korea.
Kim HR; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 Project, Yonsei University, Seoul, 03722, Republic of Korea.
Lee S; Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Lee H; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 Project, Yonsei University, Seoul, 03722, Republic of Korea.
Pak S; Cytogen, Seoul, Republic of Korea.
Amos SE; School of Human Sciences, University of Western Australia, Crawley, WA, 6009, Australia.
Vahala D; School of Human Sciences, University of Western Australia, Crawley, WA, 6009, Australia.
Park JH; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 Project, Yonsei University, Seoul, 03722, Republic of Korea.
Shin JE; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 Project, Yonsei University, Seoul, 03722, Republic of Korea.
Park SY; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 Project, Yonsei University, Seoul, 03722, Republic of Korea.
Kim HS; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Brain Korea 21 Plus Project for Medical Sciences, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Roh YH; Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, 03722, Republic of Korea.
Lee HW; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 Project, Yonsei University, Seoul, 03722, Republic of Korea.
Guan KL; Department of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Choi YS; School of Human Sciences, University of Western Australia, Crawley, WA, 6009, Australia.
Jeong J; Departments of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, 06273, Republic of Korea.
Choi J; College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea.
Roe JS; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 Project, Yonsei University, Seoul, 03722, Republic of Korea. .
Gee HY; Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. .
Park HW; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 Project, Yonsei University, Seoul, 03722, Republic of Korea. .
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2023 Mar 30; Vol. 22 (1), pp. 63. Date of Electronic Publication: 2023 Mar 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplastic Cells, Circulating*/pathology
Breast Neoplasms*/genetics
Breast Neoplasms*/pathology
Melanoma*/metabolism
Lung Neoplasms*/pathology
Mice ; Animals ; Humans ; Female ; Cell Line, Tumor ; Neoplasm Metastasis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Stratifying non-small cell lung cancer patients using an inverse of the treatment decision rules: validation using electronic health records with application to an administrative database.
Autorzy:
Kim MH; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.; Department of Preventive Medicine and Family Medicine, College of Medicine, Seoul National University, Seoul, Republic of Korea.
Park S; Department of Respiratory and Critical Care Medicine, College of Medicine, Ewha Womans University Medical Center, Seoul, Republic of Korea.
Park YR; Department of Biomedical System Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.
Ji W; Department of Respiratory and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim SG; Department of Respiratory and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Choo M; Department of Respiratory and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Department of Epidemiology, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea.
Hwang SS; Department of Epidemiology, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea.
Lee JC; Department of Oncology, College of Medicine, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea.
Kim HR; Department of Thoracic and Cardiovascular Surgery, College of Medicine, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea.
Choi CM; Department of Respiratory and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. .; Department of Oncology, College of Medicine, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea. .; Department of Pulmonary and Critical Care Medicine, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-gu, Seoul, 05505, South Korea. .
Pokaż więcej
Źródło:
BMC medical informatics and decision making [BMC Med Inform Decis Mak] 2023 Jan 06; Vol. 23 (1), pp. 3. Date of Electronic Publication: 2023 Jan 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*/diagnosis
Lung Neoplasms*/therapy
Humans ; Prognosis ; Neoplasm Staging ; Electronic Health Records ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI.
Autorzy:
Kim HR; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.; Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Jo H; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kim H; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Hong J; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Park S; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jung HA; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee SH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ahn JS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2023 Jan; Vol. 55 (1), pp. 344-349. Date of Electronic Publication: 2022 Mar 26.
Typ publikacji:
Case Reports
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Meningeal Carcinomatosis*/drug therapy
Meningeal Carcinomatosis*/genetics
Meningeal Carcinomatosis*/secondary
Humans ; ErbB Receptors ; Prospective Studies ; Protein Kinase Inhibitors/adverse effects ; Mutation
Raport
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study.
Autorzy:
Park SY; Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea.; Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Park S; Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Lee GD; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim HK; Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Choi S; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim HR; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim YH; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim DK; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Park SI; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hong TH; Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Choi YS; Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kim J; Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Cho JH; Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Shim YM; Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Zo JI; Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Na KJ; Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Park IK; Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Kang CH; Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Kim YT; Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Park BJ; Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea.
Lee CY; Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea.
Lee JG; Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea.
Kim DJ; Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea.
Paik HC; Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2023 Jan; Vol. 55 (1), pp. 94-102. Date of Electronic Publication: 2022 Jun 09.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Small Cell Lung Carcinoma*/surgery
Small Cell Lung Carcinoma*/drug therapy
Lung Neoplasms*/surgery
Lung Neoplasms*/drug therapy
Humans ; Male ; Middle Aged ; Aged ; Female ; Retrospective Studies ; Neoplasm Recurrence, Local/pathology ; Combined Modality Therapy ; Chemotherapy, Adjuvant ; Radiotherapy, Adjuvant ; Neoplasm Staging
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Sex differences in the characteristics and survival of patients with non-small-cell lung cancer: A retrospective analytical study based on real-world clinical data of the Korean population.
Autorzy:
Jeon DS; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kim JW; Respiratory and Pulmonary Disease Laboratory, Biomedical Research Center, Asan Medical Center, Seoul, South Korea.
Kim SG; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kim HR; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Song SY; Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Lee JC; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Ji W; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Choi CM; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kim HC; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Pokaż więcej
Corporate Authors:
Korean Association for Lung Cancer, South Korea Central Cancer Registry
Źródło:
Thoracic cancer [Thorac Cancer] 2022 Sep; Vol. 13 (18), pp. 2584-2591. Date of Electronic Publication: 2022 Jul 29.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma*/pathology
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/therapy
Lung Neoplasms*/drug therapy
Female ; Humans ; Male ; Neoplasm Staging ; Prognosis ; Republic of Korea/epidemiology ; Retrospective Studies ; Sex Characteristics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Autorzy:
Kim JH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.; Division of Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Ahn B; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hong SM; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jung HY; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim DH; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Choi KD; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ahn JY; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Lee JH; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Na HK; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim JH; Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim YH; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim HR; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Lee HJ; Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim SB; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Park SR; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2022 Apr; Vol. 54 (2), pp. 505-516. Date of Electronic Publication: 2021 Jun 23.
Typ publikacji:
Journal Article
MeSH Terms:
Esophageal Neoplasms*/drug therapy
Esophageal Squamous Cell Carcinoma*/drug therapy
Lung Neoplasms*/drug therapy
Aged ; Female ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Male ; Middle Aged ; Nivolumab/therapeutic use ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
Autorzy:
Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Seoul 03722, Korea.
Loong HHF; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Tsai CM; Department of Oncology, Veterans General Hospital, Taipei 112, Taiwan.
Teo MLP; ICON Cancer Centre, Hong Kong SAR, China.
Kim HR; Division of Medical Oncology, Yonsei Cancer Center, Seoul 03722, Korea.
Lim SM; Division of Medical Oncology, Yonsei Cancer Center, Seoul 03722, Korea.
Jain S; Department of Medical Affairs, Guardant Health AMEA, Singapore 138543, Singapore.
Olsen S; Department of Medical Affairs, Guardant Health AMEA, Singapore 138543, Singapore.
Park K; Sungkyunkwan University School of Medicine, Seoul 2066, Korea.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Mar 21; Vol. 29 (3), pp. 2154-2164. Date of Electronic Publication: 2022 Mar 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Circulating Tumor DNA*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
ErbB Receptors/genetics ; Humans ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins p21(ras)/genetics ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
Autorzy:
Kim HC; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ji W; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Lee JC; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim HR; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Song SY; Department of Radiation Oncology,Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Choi CM; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Pokaż więcej
Corporate Authors:
Korean Association for Lung Cancer
Korea Central Cancer Registry
Źródło:
Cancer research and treatment [Cancer Res Treat] 2021 Oct; Vol. 53 (4), pp. 1033-1041. Date of Electronic Publication: 2021 Feb 16.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Adenocarcinoma of Lung/*mortality
Carcinoma, Non-Small-Cell Lung/*mortality
Carcinoma, Squamous Cell/*mortality
Chemoradiotherapy/*mortality
Lung Neoplasms/*mortality
Pneumonectomy/*mortality
Adenocarcinoma of Lung/pathology ; Adenocarcinoma of Lung/therapy ; Aged ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/therapy ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/therapy ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/pathology ; Lung Neoplasms/therapy ; Male ; Middle Aged ; Neoplasm Staging ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma.
Autorzy:
Lee JB; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea.; Division of Hemato-oncology, Wonju Severance Christian Hospital, Yonsei University College of Medicine, Wonju, Republic of Korea.
Hong MH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea.
Park SY; Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea.
Chae S; Korea Brain Bank, Korea Brain Research Institute, Daegu, Korea.
Hwang D; Department of Biological Sciences, Seoul National University, Seoul, Korea.
Ha SJ; Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul, Korea.
Shim HS; Department of Pathology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea. .
Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Apr 20; Vol. 11 (1), pp. 8551. Date of Electronic Publication: 2021 Apr 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
B7-H1 Antigen/*metabolism
Biomarkers, Tumor/*metabolism
Carcinoma, Squamous Cell/*pathology
Lung Neoplasms/*pathology
Receptors, Virus/*metabolism
Aged ; Carcinoma, Squamous Cell/metabolism ; Carcinoma, Squamous Cell/surgery ; Humans ; Lung Neoplasms/metabolism ; Lung Neoplasms/surgery ; Prognosis ; Survival Rate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Surgical outcomes of pulmonary metastasectomy in hepatocellular carcinoma patients according to approach method: thoracoscopic versus open approach.
Autorzy:
Lee HP; Department of Thoracic & Cardiovascular Surgery, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Republic of Korea.
Yun JK; Department of Thoracic & Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jung HS; Department of Thoracic and Cardiovascular Surgery, CHA Bundang Medical Center, CHA University, Seoul, Republic of Korea.
Moon DH; Department of Thoracic and Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Lee GD; Department of Thoracic & Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Choi S; Department of Thoracic & Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim YH; Department of Thoracic & Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim DK; Department of Thoracic & Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Park SI; Department of Thoracic & Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim HR; Department of Thoracic & Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. .
Pokaż więcej
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2021 Jan 30; Vol. 19 (1), pp. 33. Date of Electronic Publication: 2021 Jan 30.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/surgery
Colorectal Neoplasms*
Liver Neoplasms*/surgery
Lung Neoplasms*/surgery
Metastasectomy*
Humans ; Male ; Neoplasm Recurrence, Local/surgery ; Pneumonectomy ; Prognosis ; Retrospective Studies ; Seoul ; Thoracic Surgery, Video-Assisted ; Thoracotomy ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Video-assisted thoracoscopic lobectomy is feasible for selected patients with clinical N2 non-small cell lung cancer.
Autorzy:
Yun JK; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Lee GD; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Choi S; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Kim HR; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Kim YH; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Park SI; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Kim DK; Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2020 Sep 16; Vol. 10 (1), pp. 15217. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung/*surgery
Lung Neoplasms/*surgery
Pneumonectomy/*methods
Thoracic Surgery, Video-Assisted/*methods
Thoracotomy/*methods
Aged ; Carcinoma, Non-Small-Cell Lung/pathology ; Feasibility Studies ; Female ; Humans ; Length of Stay ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Propensity Score ; Retrospective Studies ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer.
Autorzy:
Youn JI; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea. .; Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul, Korea. .; Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon, Korea. .; Research Institute, ProGen, Inc., Seongnam-si, Gyeonggi-do, Korea. .
Park SM; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.; Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea.
Park S; Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul, Korea.
Kim G; Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea.
Lee HJ; Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon, Korea.
Son J; Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul, Korea.
Hong MH; Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea.
Ghaderpour A; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
Baik B; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
Islam J; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
Choi JW; Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon, Korea.
Lee EY; Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon, Korea.
Kim HR; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.; Department of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul, Korea.
Seo SU; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.; Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon, Korea.
Paik S; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Yoon HI; Yonsei Cancer Center, Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea.
Jung I; Department of Biostatistics and Medical Informatics, Yonsei University College of Medicine, Seoul, Korea.
Xin CF; JE-UK Institute for Cancer Research, JEUK Co., Ltd., Gumi-City, Kyungbuk, Korea.
Jin HT; Research Institute, ProGen, Inc., Seongnam-si, Gyeonggi-do, Korea.
Cho BC; Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea.; JE-UK Institute for Cancer Research, JEUK Co., Ltd., Gumi-City, Kyungbuk, Korea.
Seong SY; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.; Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon, Korea.; Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea.
Ha SJ; Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul, Korea. .
Kim HR; Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2020 Jun 03; Vol. 10 (1), pp. 9050. Date of Electronic Publication: 2020 Jun 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung/*immunology
Killer Cells, Natural/*immunology
Lung Neoplasms/*immunology
Myeloid-Derived Suppressor Cells/*immunology
Programmed Cell Death 1 Receptor/*immunology
Adult ; Aged ; Aged, 80 and over ; B-Lymphocytes/immunology ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Female ; Humans ; Lung Neoplasms/drug therapy ; Male ; Middle Aged ; Nivolumab/therapeutic use ; Progression-Free Survival ; Prospective Studies ; T-Lymphocytes/immunology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma.
Autorzy:
Kim SY; JEUK Institute for Cancer Research, JEUK Co.,Ltd., Gumi-City, Kyungbuk, Korea.; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Lee JY; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kim DH; JEUK Institute for Cancer Research, JEUK Co.,Ltd., Gumi-City, Kyungbuk, Korea.; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Joo H-; JEUK Institute for Cancer Research, JEUK Co.,Ltd., Gumi-City, Kyungbuk, Korea.; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Yun MR; JEUK Institute for Cancer Research, JEUK Co.,Ltd., Gumi-City, Kyungbuk, Korea.; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Jung D; Severance Biomedical Science Institute, Yonsei University of College of Medicine, Seoul, Korea.
Yun J; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Heo SG; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Ahn B-; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Park CW; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Pyo KH; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Chun YJ; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Hong MH; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kim HR; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. .
Cho BC; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Dec 27; Vol. 9 (1), pp. 19909. Date of Electronic Publication: 2019 Dec 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma of Lung/*therapy
Lung Neoplasms/*therapy
Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/metabolism ; Cell Line ; Cell Survival/genetics ; Cell Survival/physiology ; ErbB Receptors/genetics ; Flow Cytometry ; Humans ; Immunoblotting ; Lung Neoplasms/drug therapy ; Lung Neoplasms/metabolism ; Mutation/genetics ; Protein Kinase Inhibitors/therapeutic use ; Exome Sequencing
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
Autorzy:
Chun YJ; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Choi JW; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.; Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea.
Hong MH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Jung D; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Son H; Department of Biomedical Systems Informatics, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Cho EK; Division of Hematology-Oncology, Department of Internal Medicine, Gachon Medical School, Gil Medical Center, Incheon, Korea.
Min YJ; Division of Hematology and Oncology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Kim SW; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Park K; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee SS; Department of Hematology-Oncology, Inje University Haeundae Paik Hospital, Busan, Korea.
Kim S; Department of Biomedical Systems Informatics, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Cho BC; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Pokaż więcej
Corporate Authors:
Korean Lung Cancer Consortium (KLCC)
Źródło:
PloS one [PLoS One] 2019 Nov 25; Vol. 14 (11), pp. e0224379. Date of Electronic Publication: 2019 Nov 25 (Print Publication: 2019).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma of Lung/*genetics
Antineoplastic Agents/*therapeutic use
Biomarkers, Tumor/*genetics
Lung Neoplasms/*genetics
Precision Medicine/*methods
Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/mortality ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacology ; Asian People/genetics ; Biomarkers, Tumor/antagonists & inhibitors ; DNA Mutational Analysis ; Disease-Free Survival ; Feasibility Studies ; Female ; Follow-Up Studies ; High-Throughput Nucleotide Sequencing ; Humans ; Lung/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Mutation ; Republic of Korea/epidemiology ; Smoking/epidemiology ; Exome Sequencing
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 37

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies